小鼠前额叶皮层中的 RGS4 作用可调节对慢性应激和氯胺酮的行为和转录组反应。

IF 3.2 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Vasiliki Mitsi, Anne Ruiz, Claire Polizu, Zahra Farzinpour, Aarthi Ramakrishnan, Randal A Serafini, Eric M Parise, Madeline Floodstrand, Omar K Sial, Sevasti Gaspari, Cheuk Y Tang, Eric J Nestler, Eric F Schmidt, Li Shen, Venetia Zachariou
{"title":"小鼠前额叶皮层中的 RGS4 作用可调节对慢性应激和氯胺酮的行为和转录组反应。","authors":"Vasiliki Mitsi, Anne Ruiz, Claire Polizu, Zahra Farzinpour, Aarthi Ramakrishnan, Randal A Serafini, Eric M Parise, Madeline Floodstrand, Omar K Sial, Sevasti Gaspari, Cheuk Y Tang, Eric J Nestler, Eric F Schmidt, Li Shen, Venetia Zachariou","doi":"10.1124/molpharm.123.000753","DOIUrl":null,"url":null,"abstract":"<p><p>The signal transduction protein, regulator of G protein signaling 4 (RGS4), plays a prominent role in physiologic and pharmacological responses by controlling multiple intracellular pathways. Our earlier work identified the dynamic but distinct roles of RGS4 in the efficacy of monoamine-targeting versus fast-acting antidepressants. Using a modified chronic variable stress (CVS) paradigm in mice, we demonstrate that stress-induced behavioral abnormalities are associated with the downregulation of RGS4 in the medial prefrontal cortex (mPFC). Knockout of RGS4 (RGS4KO) increases susceptibility to CVS, as mutant mice develop behavioral abnormalities as early as 2 weeks after CVS resting-state functional magnetic resonance imaging I (rs-fMRI) experiments indicate that stress susceptibility in RGS4KO mice is associated with changes in connectivity between the mediodorsal thalamus (MD-THL) and the mPFC. Notably, RGS4KO also paradoxically enhances the antidepressant efficacy of ketamine in the CVS paradigm. RNA-sequencing analysis of naive and CVS samples obtained from mPFC reveals that RGS4KO triggers unique gene expression signatures and affects several intracellular pathways associated with human major depressive disorder. Our analysis suggests that ketamine treatment in the RGS4KO group triggers changes in pathways implicated in synaptic activity and responses to stress, including pathways associated with axonal guidance and myelination. Overall, we show that reducing RGS4 activity triggers unique gene expression adaptations that contribute to chronic stress disorders and that RGS4 is a negative modulator of ketamine actions. SIGNIFICANCE STATEMENT: Chronic stress promotes robust maladaptation in the brain, but the exact intracellular pathways contributing to stress vulnerability and mood disorders have not been thoroughly investigated. In this study, the authors used murine models of chronic stress and multiple methodologies to demonstrate the critical role of the signal transduction modulator regulator of G protein signaling 4 in the medial prefrontal cortex in vulnerability to chronic stress and the efficacy of the fast-acting antidepressant ketamine.</p>","PeriodicalId":18767,"journal":{"name":"Molecular Pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949159/pdf/","citationCount":"0","resultStr":"{\"title\":\"RGS4 Actions in Mouse Prefrontal Cortex Modulate Behavioral and Transcriptomic Responses to Chronic Stress and Ketamine.\",\"authors\":\"Vasiliki Mitsi, Anne Ruiz, Claire Polizu, Zahra Farzinpour, Aarthi Ramakrishnan, Randal A Serafini, Eric M Parise, Madeline Floodstrand, Omar K Sial, Sevasti Gaspari, Cheuk Y Tang, Eric J Nestler, Eric F Schmidt, Li Shen, Venetia Zachariou\",\"doi\":\"10.1124/molpharm.123.000753\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The signal transduction protein, regulator of G protein signaling 4 (RGS4), plays a prominent role in physiologic and pharmacological responses by controlling multiple intracellular pathways. Our earlier work identified the dynamic but distinct roles of RGS4 in the efficacy of monoamine-targeting versus fast-acting antidepressants. Using a modified chronic variable stress (CVS) paradigm in mice, we demonstrate that stress-induced behavioral abnormalities are associated with the downregulation of RGS4 in the medial prefrontal cortex (mPFC). Knockout of RGS4 (RGS4KO) increases susceptibility to CVS, as mutant mice develop behavioral abnormalities as early as 2 weeks after CVS resting-state functional magnetic resonance imaging I (rs-fMRI) experiments indicate that stress susceptibility in RGS4KO mice is associated with changes in connectivity between the mediodorsal thalamus (MD-THL) and the mPFC. Notably, RGS4KO also paradoxically enhances the antidepressant efficacy of ketamine in the CVS paradigm. RNA-sequencing analysis of naive and CVS samples obtained from mPFC reveals that RGS4KO triggers unique gene expression signatures and affects several intracellular pathways associated with human major depressive disorder. Our analysis suggests that ketamine treatment in the RGS4KO group triggers changes in pathways implicated in synaptic activity and responses to stress, including pathways associated with axonal guidance and myelination. Overall, we show that reducing RGS4 activity triggers unique gene expression adaptations that contribute to chronic stress disorders and that RGS4 is a negative modulator of ketamine actions. SIGNIFICANCE STATEMENT: Chronic stress promotes robust maladaptation in the brain, but the exact intracellular pathways contributing to stress vulnerability and mood disorders have not been thoroughly investigated. In this study, the authors used murine models of chronic stress and multiple methodologies to demonstrate the critical role of the signal transduction modulator regulator of G protein signaling 4 in the medial prefrontal cortex in vulnerability to chronic stress and the efficacy of the fast-acting antidepressant ketamine.</p>\",\"PeriodicalId\":18767,\"journal\":{\"name\":\"Molecular Pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949159/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1124/molpharm.123.000753\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1124/molpharm.123.000753","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

信号转导蛋白--G蛋白信号转导调节器4(RGS4)通过控制多种细胞内通路,在生理和药理反应中发挥着重要作用。我们早先的研究发现,RGS4 在单胺靶向抗抑郁药与速效抗抑郁药的疗效中发挥着动态但不同的作用。我们利用改良的小鼠慢性可变应激(CVS)范例证明,应激诱导的行为异常与内侧前额叶皮层(mPFC)中 RGS4 的下调有关。RGS4基因敲除(RGS4KO)会增加对CVS的易感性,因为突变小鼠早在CVS两周后就会出现行为异常。静息态 fMRI(rs-fMRI)实验表明,RGS4KO 小鼠的应激易感性与丘脑内侧(MD-THL)和 mPFC 之间的连接变化有关。值得注意的是,RGS4KO还在CVS范式中矛盾地增强了氯胺酮的抗抑郁功效。对从mPFC获得的幼稚样本和CVS样本进行的RNA测序(RNA-seq)分析表明,RGS4KO会触发独特的基因表达特征,并影响与人类重度抑郁障碍(MDD)相关的几种细胞内通路。我们的分析表明,氯胺酮治疗 RGS4KO 组会引发突触活动和应激反应相关通路的变化,包括与轴突导向和髓鞘化相关的通路。总之,我们的研究表明,降低 RGS4 的活性会引发独特的基因表达适应性,从而导致慢性应激障碍,而且 RGS4 是氯胺酮作用的负调制剂。意义声明 慢性应激会导致大脑出现严重的适应不良,但导致应激脆弱性和情绪失调的确切细胞内途径尚未得到深入研究。在这项研究中,我们利用小鼠慢性应激模型和多种方法证明了mPFC中的信号转导调节器RGS4在慢性应激易感性和速效抗抑郁剂氯胺酮的疗效中的关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
RGS4 Actions in Mouse Prefrontal Cortex Modulate Behavioral and Transcriptomic Responses to Chronic Stress and Ketamine.

The signal transduction protein, regulator of G protein signaling 4 (RGS4), plays a prominent role in physiologic and pharmacological responses by controlling multiple intracellular pathways. Our earlier work identified the dynamic but distinct roles of RGS4 in the efficacy of monoamine-targeting versus fast-acting antidepressants. Using a modified chronic variable stress (CVS) paradigm in mice, we demonstrate that stress-induced behavioral abnormalities are associated with the downregulation of RGS4 in the medial prefrontal cortex (mPFC). Knockout of RGS4 (RGS4KO) increases susceptibility to CVS, as mutant mice develop behavioral abnormalities as early as 2 weeks after CVS resting-state functional magnetic resonance imaging I (rs-fMRI) experiments indicate that stress susceptibility in RGS4KO mice is associated with changes in connectivity between the mediodorsal thalamus (MD-THL) and the mPFC. Notably, RGS4KO also paradoxically enhances the antidepressant efficacy of ketamine in the CVS paradigm. RNA-sequencing analysis of naive and CVS samples obtained from mPFC reveals that RGS4KO triggers unique gene expression signatures and affects several intracellular pathways associated with human major depressive disorder. Our analysis suggests that ketamine treatment in the RGS4KO group triggers changes in pathways implicated in synaptic activity and responses to stress, including pathways associated with axonal guidance and myelination. Overall, we show that reducing RGS4 activity triggers unique gene expression adaptations that contribute to chronic stress disorders and that RGS4 is a negative modulator of ketamine actions. SIGNIFICANCE STATEMENT: Chronic stress promotes robust maladaptation in the brain, but the exact intracellular pathways contributing to stress vulnerability and mood disorders have not been thoroughly investigated. In this study, the authors used murine models of chronic stress and multiple methodologies to demonstrate the critical role of the signal transduction modulator regulator of G protein signaling 4 in the medial prefrontal cortex in vulnerability to chronic stress and the efficacy of the fast-acting antidepressant ketamine.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molecular Pharmacology
Molecular Pharmacology 医学-药学
CiteScore
7.20
自引率
2.80%
发文量
50
审稿时长
3-6 weeks
期刊介绍: Molecular Pharmacology publishes findings derived from the application of innovative structural biology, biochemistry, biophysics, physiology, genetics, and molecular biology to basic pharmacological problems that provide mechanistic insights that are broadly important for the fields of pharmacology and toxicology. Relevant topics include: Molecular Signaling / Mechanism of Drug Action Chemical Biology / Drug Discovery Structure of Drug-Receptor Complex Systems Analysis of Drug Action Drug Transport / Metabolism
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信